SVP, Clinical Development Operations · DiaMedica Therapeutics Inc. (DMAC)

Julie Daves

FY2023 is the first fiscal year CompBrief holds for Julie Daves as a named executive officer of DiaMedica Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$533,370

Salary $306,754Stock awards $0

4th of 4 named executive officers at DiaMedica Therapeutics by FY2023 total.

4 named officers on file for DiaMedica Therapeutics, FY2023

Julie Daves’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • DMAC’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how DiaMedica Therapeutics’s whole pay program stands against its peers

  • DiaMedica Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DMAC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 4, 2024 (DEF 14A).

Free

Get Julie Daves’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Julie Daves compensation by year

DiaMedica Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as DiaMedica Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$306,754
Bonus$0
Stock awards$0
Option awards$118,309
Non-equity incentive$91,657
Pension and deferred compensation$0
All other$16,650
Total$533,370

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: DiaMedica Therapeutics Inc. DEF 14A filed April 4, 2024, accession 0001437749-24-010985, and prior-year filings.

How this page was built: the DiaMedica Therapeutics Inc. filed document, accession 0001437749-24-010985. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option78,750—$1.47
Option54,000—$2.73

Per the Outstanding Equity Awards at Fiscal Year-End table in DiaMedica Therapeutics Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

DiaMedica Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Rick PaulsPresident and Chief Executive Officer$1,215,161
Scott KellenChief Financial Officer and Secretary$632,215
Kirsten GruisFormer Chief Medical Officer$596,083
Julie Daves · this pageSVP, Clinical Development Operations$533,370

The full DiaMedica Therapeutics compensation record

free company brief

This page is one person within DiaMedica Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the DiaMedica Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are DiaMedica Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Julie Daves's compensation dossier · One-time report. No refunds.